Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Verzenio

- PMLiVE

AbbVie’s Rinvoq receives FDA approval for Crohn’s disease

Inflammatory bowel disease affects nearly one in every 100 people in the US

- PMLiVE

Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee

Up to 80,000 children aged under five are hospitalised each year in the US due to RSV infection

- PMLiVE

AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval

Approximately 150,000 new cases of DLBCL are diagnosed globally each year

- PMLiVE

FDA advisory committee backs Sarepta’s Duchenne muscular dystrophy gene therapy

The disease occurs in up to one in every 5,000 newborn males worldwide

- PMLiVE

Astellas Pharma’s non-hormonal menopause drug granted FDA approval

Vasomotor symptoms affect up to 80% of menopausal individuals in the US

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in US

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

GSK’s RSV vaccine approved by FDA for older adults

Arexvy is the first RSV vaccine for this age group to be approved anywhere in the world

- PMLiVE

Eli Lilly’s Alzheimer’s drug shown to significantly slow disease progression in phase 3 trial

Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo

- PMLiVE

FDA issues new draft guidance on decentralised clinical trials

The document includes recommendations on trial design and the use of digital health technologies

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Pfizer’s next-generation pneumococcal vaccine granted FDA approval

The vaccine can help protect against 20 serotypes of the streptococcus pneumoniae bacteria

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links